Prosecution Insights
Last updated: April 19, 2026

Examiner: HOLLAND, PAUL J

Tech Center 1600 • Art Units: 1636 1653 1656

This examiner grants 58% of resolved cases

Performance Statistics

57.5%
Allow Rate
-2.5% vs TC avg
819
Total Applications
+65.3%
Interview Lift
1145
Avg Prosecution Days
Based on 764 resolved cases, 2023–2026

Rejection Statute Breakdown

8.0%
§101 Eligibility
18.6%
§102 Novelty
31.6%
§103 Obviousness
29.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19071005 PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF Non-Final OA Halozyme, Inc.
19071055 PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF Non-Final OA Halozyme, Inc.
18548640 REDUCING HIGH MANNOSE GLYCAN PROTEIN EXPRESSION USING GUANOSINE 5'-MONOPHOSPHATE Non-Final OA MERCK SHARP & DOHME LLC
18278695 METHODS FOR GENERATING A CRISPR ARRAY Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18016428 COMPOSITIONS AND METHODS FOR TREATING AN INHERITED RETINAL DISEASE Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17997877 ACE2 COMPOSITIONS AND METHODS Final Rejection The Regents of the University of California
17767844 METHODS TO STABILIZE MAMMALIAN CELLS Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18030700 BACILLUS CELL WITH REDUCED LIPASE AND/OR ESTERASE SIDE ACTIVITIES Non-Final OA BASF SE
19293034 MUTANTS OF IMMUNOGLOBULIN-DEGRADING ENZYME IDEE Final Rejection SHANGHAI BAO PHARMACEUTICALS CO., LTD.
18021135 CELL HAVING GENE CORRECTED EX VIVO AND USE THEREOF Non-Final OA IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
18015753 SELF-ELIMINATING TRANSGENES Non-Final OA The Texas A&M University System
17726324 GENETICALLY MODIFIED RECOMBINANT CELL LINES Final Rejection Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
18033166 Compositions and Methods Relating to Alzheimer's Disease Non-Final OA Duke University
17604714 METHODS OF IMPROVING THE LONGEVITY OF IMMUNE CELLS Non-Final OA University of Houston System
17921035 CHIMERIC POLYPEPTIDES AND METHODS OF PREPARING SAME Non-Final OA RAMOT AT TEL-AVIV UNIVERSITY LTD.
17620557 PRODUCTION OF VECTORS USING PHAGE ORIGIN OF REPLICATION Final Rejection ASKBIO INC.
18014348 CLEANING COMPOSITIONS AND USES THEREOF Non-Final OA Henkel AG & Co. KGaA
17786561 CLEANING COMPOSITIONS COMPRISING DISPERSINS VIII Final Rejection Henkel AG & Co. KGaA
17820488 RETINAL ORGANOID MODEL SYSTEMS Non-Final OA Wisconsin Alumni Research Foundation
16978461 EXPRESSION OF HETEROLOGOUS ENZYMES IN YEAST FOR FLAVOURED ALCOHOLIC BEVERAGE PRODUCTION Non-Final OA Danstar Ferment AG
17793753 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) Non-Final OA The United States of America,as represented by the Secretary,Department of Health and Human Services
17525433 CELL ENGINEERING USING RNAs Non-Final OA Boehringer Ingelheim International GmbH
17627088 PRODUCTION OF FUCOSYLLACTOSE IN HOST CELLS Non-Final OA INBIOSE N.V.
18283614 REDUCING HOST CELL IMPURITIES DURING RECOMBINANT PROTEIN PRODUCTION Non-Final OA Biogen MA Inc.
18680688 FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR PLANT HEALTH Non-Final OA Spogen Biotech Inc.
18434301 DELIVERY OF ACTIVE AGENTS Final Rejection MannKind Corporation
17635349 COMPOSITIONS AND METHODS FOR INCREASED PROTEIN PRODUCTION IN BACILLUS LICHENIFORMIS Non-Final OA DANISCO US INC.
18628548 METHODS FOR PRODUCING BIOGAS AND RENEWABLE NATURAL GAS USING CO-PRODUCTS FROM A STILLAGE STREAM AS FEEDSTOCKS Non-Final OA Marquis IP LLC
18444368 COMPOSITIONS AND METHODS FOR GENE EDITING Final Rejection CRISPR THERAPEUTICS AG
18376543 Composition and Method of an Orally Administered Antimicrobial Peptide Vectored in a Bacterial Expression Vehicle Non-Final OA The United States of America as represented by the Secretary of Agriculture

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month